Week Ending June 14, 2021

ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more
“The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.”

How Do Immunotherapy Treatments Work for Small Cell Lung Cancer?
“Small cell lung cancer (SCLC) is a less common but aggressive type of lung cancer. Symptoms of SCLC often don’t show up until later stages of cancer, when it has spread to other areas of the body.”

Radiologists and others launching large-scale initiative to tackle incidental lung nodule blind spot
“Radiologists, pulmonologists and other lung care stakeholders are launching a nationwide initiative to tackle ongoing challenges addressing incidental pulmonary nodules that may turn out to be cancerous.”

Opdivo-Yervoy Combination Could Benefit Patients with Non-Small Cell Lung Cancer
“After a four year follow up, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continued to prolong survival in patients with advanced non-small cell lung cancer, according to findings presented at the virtual 2021 ASCO Annual Meeting.”

Amgen Lung Cancer Drug Approved by FDA
“The U.S. Food and Drug Administration gave accelerated approval to Lumakras, a drug from Amgen Inc. for adult patients with non-small cell lung cancer.”

Study Explores Potential of Liquid Biopsy in Early-Stage NSCLC
“The study explores data on liquid biopsy approaches outside of circulating tumor DNA—a commonly used approach for liquid biopsy—and includes novel methods like non-coding RNA.”

Cedars-Sinai Cancer names thoracic medical oncology director
“Sukhmani K. Padda, MD, has been selected to direct thoracic medical oncology at Cedars-Sinai Cancer. Padda’s research focuses on therapies for thoracic cancers. She has a particular interest in improving treatment for patients with rare thoracic tumors — such as thymic malignancies and lung neuroendocrine tumors — and genomic subsets of lung cancer, such as KRAS- and EGFR-positive tumors. Padda also conducts research into tumor biomarkers to help ensure optimal treatment.”

Rationale for the GEMSTONE-302 Study in Lung Cancer
“Jamie E. Chaft, MD, discusses the background behind the phase 3 GEMSTONE-302 trial of platinum-based chemotherapy with placebo or CS1001 as front-line treatment for patients with advanced non-small cell lung cancer.”